• There is currently no evidence-based treatment for the smallest babies with malaria

• The CALINA study tested a new ratio and dose of Coartem^® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg

• The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review

Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from the